Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
ISSN: 2155-9899
Andrew JS Furness, Kroopa Joshi, Karl S Peggs and Sergio A Quezada
Immune modulatory antibody-based therapies serve to augment and direct the endogenous immune response against cancer. Significant efficacy has been demonstrated in multiple subtypes of solid and haematological malignancies. Despite great promise, responses are limited to a fraction of treated patients highlighting the need to decipher underlying mechanisms of response and resistance. Here we review progress in this area with a focus on the identification of candidate predictive biomarkers of response.